Immunotherapy plus chemo takes on tough breast cancer
NCT ID NCT06318897
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 28 times
Summary
This phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin and paclitaxel) can improve outcomes for people with stage 1 triple-negative breast cancer. The study will enroll 28 participants at MD Anderson Cancer Center and will monitor safety and side effects. Triple-negative breast cancer is an aggressive type that lacks common treatment targets, so new approaches are needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) plus carboplatin and paclitaxel chemotherapy
What this could lead to
If successful, this could offer a more effective treatment option for early-stage triple-negative breast cancer, potentially reducing the risk of recurrence.
What could go wrong
This is a small, early-phase study with only 28 participants, so results may not apply to all patients. The combination may cause significant side effects, and it's not yet known if it works better than standard treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.